Back to Journals » Nature and Science of Sleep » Volume 11

Novel non-pharmacological insomnia treatment – a pilot study

Authors Pavlova MK, Latreille V, Puri N, Johnsen J, Batool-Anwar S, Javaheri S, Mathew PG

Received 29 December 2018

Accepted for publication 10 June 2019

Published 11 September 2019 Volume 2019:11 Pages 189—195

DOI https://doi.org/10.2147/NSS.S198944

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Melinda Thomas

Peer reviewer comments 2

Editor who approved publication: Dr Sutapa Mukherjee


Milena K Pavlova,1 Véronique Latreille,1 Nirajan Puri,1 Jami Johnsen,1 Salma Batool-Anwar,2 Sogol Javaheri,2 Paul G Mathew1

1Department of Neurology, Harvard Medical School, Brigham and Women’s Hospital, Boston, MA, USA; 2Department of Medicine, Harvard Medical School, Brigham and Women’s Hospital, Boston, MA, USA

Correspondence: Milena K Pavlova
Department of Neurology, Brigham and Women’s Hospital, 75 Francis Street, Boston, MA 02115, USA
Tel +1 617 983 7580
Fax +1 617 983 7582
Email mpavlova@bwh.harvard.edu

Objective: The objective of this prospective pilot study was to examine the effects of a novel non-pharmacological device (BioBoosti) on insomnia symptoms in adults.
Methods: Subjects with chronic insomnia were instructed to hold the device in each hand for 8 mins for 6 cycles on a nightly basis for 2 weeks. Outcomes tested included standardized subjective sleep measures assessing sleep quality, insomnia symptoms, and daytime sleepiness. Sleep was objectively quantified using electroencephalogram (EEG) before and after 2 weeks of treatment with BioBoosti, and wrist actigraphy throughout the study.
Results: Twenty adults (mean age: 45.6±17.1 y/o; range 18–74 y/o) were enrolled in the study. No significant side effects were noted by any of the subjects. After 2 weeks of BioBoosti use, subjects reported improved sleep quality (Pittsburgh Sleep Quality Index: 12.6±3.3 versus 8.5±3.7, p=0.001) and reduced insomnia symptoms (Insomnia Severity Index: 18.2±5.2 versus 12.8±7.0, p<0.001). Sleepiness, as assessed by a visual analog scale, was significantly reduced after treatment (5.7±2.8 versus 4.0±3.3, p=0.03).
Conclusion: BioBoosti use yielded an improvement in insomnia symptoms. Larger placebo-controlled studies are needed to fully assess efficacy.

Keywords: insomnia, non-pharmacological treatment, sleep quality, actigraphy, electroencephalography

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]